Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
The DOI matches its Crossref record.
Abstract
PURPOSE: We conducted a phase I trial of the cyclin-dependent kinase inhibitor, flavopiridol (National Service Center [NSC] 649890), to determine the maximum-tolerated dose (MTD), toxicity profile, and pharmacology of flavopiridol given as a 72-hour infusion every 2 weeks. PATIENTS AND METHODS: Seventy-six patients with refractory malignancies with prior disease progression were treated with flavopiridol, with first-cycle pharmacokinetic sampling. RESULTS: Forty-nine patients defined our first MTD, 50 mg/m2/d x 3 with dose-limiting toxicity (DLT) of secretory diarrhea at 62.5 mg/kg/d x 3. Subsequent patients received antidiarrheal prophylaxis (ADP) to define a second MTD, 78 mg/m2/d x 3 with DLT of hypotension at 98 mg/m2/d x 3. Other toxicities included a proinflammatory syndrome with alterations in acute-phase reactants, particularly at doses >50 mg/ m2/d x 3, which in some patients prevented chronic therapy every 2 weeks. In some patients, ADP was not successful, requiring dose-deescalation. Although approximately 70% of patients displayed predictable flavopiridol pharmacology, we observed unexpected interpatient variability and postinfusion peaks in approximately 30% of cases. At the two MTDs, we achieved a mean plasma flavopiridol concentration of 271 nM (50 mg/m2/d x 3) and 344 nM (78 mg/m2/d x 3), respectively. One partial response in a patient with renal cancer and minor responses (n=3) in patients with non-Hodgkin's lymphoma, colon, and renal cancer occurred. CONCLUSION: The MTD of infusional flavopiridol is 50 mg/m2/d x 3 with dose-limiting secretory diarrhea at 62.5 mg/m2/d x 3. With ADP, 78 mg/m2/d x 3 was the MTD, with dose-limiting hypotension at 98 mg/m2/d x 3. Based on chronic tolerability, 50 mg/m2/d x 3 is the recommended phase II dose without ADP. Antitumor effect was observed in certain patients with renal, prostate, and colon cancer, and non-Hodgkin's lymphoma. Concentrations of flavopiridol (200 to 400 nM) needed for cyclin-dependent kinase inhibition in preclinical models were achieved safely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Leclerc, S., Garnier, M., Hoessel, R., Marko, D., Bibb, J. A., Snyder, G. L., Greengard, P., Biernat, J., Wu, Y.-Z., Mandelkow, E.-M., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002466200 · Cited by 723
Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo
Chao, S.-H., & Price, D. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102306200 · Cited by 621
Natural products in anticancer therapy
da Rocha, A. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00063-7 · Cited by 604
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Senderowicz, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 492
Self-citationAnticancer drug targets: cell cycle and checkpoint control
Shapiro, G. I., & Harper, J. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9054 · Cited by 464
Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication
Chao, S.-H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., & Price, D. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000446200 · Cited by 455
Self-citationThe molecular basis and potential role of survivin in cancer diagnosis and therapy
Altieri, D. C. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02243-2 · Cited by 412
Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M., Blum, K. A., Rovin, B., Brooker-McEldowney, M., et al. (2007) · Blood · doi:10.1182/blood-2006-05-020735 · Cited by 390
Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., et al. (2001) · Genome Biology · doi:10.1186/gb-2001-2-10-research0041 · Cited by 370
Self-citationFlavonoids Are Inhibitors of Breast Cancer Resistance Protein (ABCG2)-Mediated Transport
Zhang, S., Yang, X., & Morris, M. E. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.5.1208 · Cited by 359
Sarno, S., Reddy, H., Meggio, F., Ruzzene, M., Davies, S. P., Donella-Deana, A., Shugar, D., & Pinna, L. A. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02404-8 · Cited by 356
Schultz, C., Link, A., Leost, M., Zaharevitz, D. W., Gussio, R., Sausville, E. A., Meijer, L., & Kunick, C. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9900570 · Cited by 334
Self-citationFlavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials
Senderowicz, A. M. (1999) · Investigational New Drugs · doi:10.1023/a:1006353008903 · Cited by 330
Self-citationCyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation
Sielecki, T. M., Boylan, J. F., Benfield, P. A., & Trainor, G. L. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990256j · Cited by 323
Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols
Gupta, S. C., Tyagi, A. K., Deshmukh-Taskar, P., Hinojosa, M., Prasad, S., & Aggarwal, B. B. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.06.006 · Cited by 313
Kouroukis, C. T., Belch, A., Crump, M., Eisenhauer, E., Gascoyne, R. D., Meyer, R., Lohmann, R., Lopez, P., Powers, J., Turner, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.057 · Cited by 277
Bramson, H. N., Corona, J., Davis, S. T., Dickerson, S. H., Edelstein, M., Frye, S. V., Gampe, R. T., Harris, P. A., Hassell, A., Holmes, W. D., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010117d · Cited by 269
Benson, C., White, J., Bono, J. D., O'Donnell, A., Raynaud, F., Cruickshank, C., McGrath, H., Walton, M., Workman, P., Kaye, S., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603509 · Cited by 261
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
Chen, R., Keating, M. J., Gandhi, V., & Plunkett, W. (2005) · Blood · doi:10.1182/blood-2005-04-1678 · Cited by 259
Current Perspectives in the Application of Medicinal Plants Against Cancer: Novel Therapeutic Agents
Gezici, S., & Şekeroğlu, N. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666181224121004 · Cited by 258
Mans, D. R. A., Rocha, A. B., & Schwartsmann, G. (2000) · The Oncologist · doi:10.1634/theoncologist.5-3-185 · Cited by 254
Misra, R. N., Xiao, H.-Y., Kim, K. S., Lu, S., Han, W.-C., Barbosa, S. A., Hunt, J. T., Rawlins, D. B., Shan, W., Ahmed, S. Z., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0305568 · Cited by 252
Patel, V, Senderowicz, A. M., Pinto, D., Igishi, T., Raffeld, M., Quintanilla-Martinez, L., Ensley, J. F., Sausville, E. A., & Gutkind, J. S. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3661 · Cited by 246
“Phase I clinical trials have been completed recently in patients with refractory neoplasms (18).”
BackgroundResultSelf-citationThe CDK inhibitors in cancer research and therapy
Cicenas, J., & Valius, M. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1039-4 · Cited by 243
“antitumor eVect in patients with renal, prostate and colon cancer, metastatic gastric cancer and non-Hodgkin’s lymphoma (Senderowicz et al. 1998; Tan et al. 2002; Thomas et al. 2002; Whitlock et al. 2005).”
Stadler, W. M., Vogelzang, N. J., Amato, R., Sosman, J., Taber, D., Liebowitz, D., & Vokes, E. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.371 · Cited by 208
The therapeutic potential of flavonoids
Wang, H.-K. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.9.2103 · Cited by 206
“Concentrations of flavopiridol (200 - 400 nM) needed for CDK inhibition in preclinical models were achieved safely [27].”
MethodHonma, T., Hayashi, K., Aoyama, T., Hashimoto, N., Machida, T., Fukasawa, K., Iwama, T., Ikeura, C., Ikuta, M., Suzuki-Takahashi, I., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0103256 · Cited by 203
Cyclin dependent kinases in cancer: Potential for therapeutic intervention
Canavese, M., Santo, L., & Raje, N. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.19589 · Cited by 159
“continuous infusion every 2 weeks in two phase I trials in humans.(25,26) Despite promising preclinical results, clinical activity observed with Flavopiridol has been generally disappointing in a variety of solid tumors when used as a single agent.”
BackgroundLuke, J. J., D'Adamo, D. R., Dickson, M. A., Keohan, M. L., Carvajal, R. D., Maki, R. G., de Stanchina, E., Musi, E., Singer, S., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3203 · Cited by 95
Marine organisms and other novel natural sources of new cancer drugs
Schwartsmann, G. (2000) · Annals of Oncology · doi:10.1093/annonc/11.suppl_3.235 · Cited by 81
Laderian, B., & Fojo, T. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.03.006 · Cited by 77
Metadata
- Authors
- Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., Arbuck, S. G., & Sausville, E. A.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-09
- Volume
- 16
- Issue
- 9
- Pages
- 2986-2999
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1777669545
- Cited by
- 403
- References
- 0
- FWCI
- 15.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.